Physician profile
Barton D Parish
NPI 1013922988
$2,870.36
in general payments reported to CMS, 2019-2025
26 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.98 · 2020: $190 · 2021: $559 · 2022: $555 · 2023: $442 · 2024: $587 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,027.41 | 2021-2025 | |
| Glaxosmithkline, LLC. | $347.11 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $222.90 | 2019-2025 | |
| Lilly USA, LLC | $205.37 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $161.44 | 2020-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $140.73 | 2022-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $108.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $102.54 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $63.05 | 2022-2025 | Cardiomems, Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $58.45 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $49.37 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.77 | 2019-2021 | |
| Shield Therapeutics INC | $45.30 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $39.98 | 2021-2024 | Veozah |
| Edwards Lifesciences Corporation | $37.74 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $36.57 | 2021-2025 | Rexulti |
| Eisai INC. | $25.65 | 2020 | |
| Antares Pharma, INC. | $21.16 | 2025 | Xyosted |
| Dexcom, INC. | $20.66 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $17.60 | 2022 | |
| Halozyme INC | $16.66 | 2023 | |
| Sanofi Pasteur INC. | $16.65 | 2021 | |
| Esperion Therapeutics, INC. | $16.62 | 2022 | |
| Horizon Therapeutics Plc | $14.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.84 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barton Parish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.